Table 1 Characteristics of late stage (stage III & IV) Hepatocellular Carcinoma (HCC) patients undergoing dual-tracer PET-CT for staging
Overall | [11C]- acetate avid HCC | [11C]-acetate non-avid HCC (%) | P | |
|---|---|---|---|---|
No of Patients | 51 | 38 | 13 | |
Median age (years) | 60.1 (± 14.4) | 61.8 | 59.1 | 0.57 |
Gender (% male) | 44 (86.3%) | 33 (86.8%) | 11 (84.6%) | > 0.99 |
Serum AFP (ng/ml) | 30,351.6 (± 89,763.5) | 29,779.4 (± 88,934.9) | 30,353.0(± 89,763.2) | 0.04 |
Aetiology | ||||
Hepatitis B | 34 (66.7%) | 24 (63.2%) | 10 (76.9%) | 0.50 |
Hepatitis C | 3 (5.9%) | 3 (7.9%) | 0 (0.0%) | 0.56 |
Multiple etiologies | 18 (35.3%) | 13 (34.2) | 5 (38.5) | > 0.99 |
Tumor features | ||||
HCC staging III/IV (%) | 33 (64.7%) | 25 (65.8%) | 8 (61.5%) | > 0.99 |
Tumor size (cm) | 10.4 (± 5.49) | 9.0 | 14.4 | 0.12 |
Focal disease (%) | 29 (56.9%) | 23 (60.5%) | 6 (46.2%) | 0.52 |
PV thrombosis (%) | 39 (76.5%) | 29 (76.3%) | 10 (76.9%) | > 0.99 |
[18F]-FDG avid (%) | 40 (78.4%) | 27 (71.1%) | 13 (100%) | 0.046 |
Treatment | ||||
Resection (%) | 12 (23.5%) | 9 (23.7%) | 3 (23.1) | > 0.99 |
TACE (%) | 11 (21.6%) | 7 (18.4) | 4 (30.8) | 0.70 |
SIRT (%) | 5 (9.8%) | 5 (13.2) | 0 (0) | 0.31 |
Systemic therapy (%) | 5 (9.8%) | 5 (13.2) | 0 (0) | 0.31 |